DDInter392 DDInter596
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Cladribine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) upregulates {v} (Gene) FOSL1
FOSL1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) causes {v} (Side Effect) Infestation NOS
Infestation NOS {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Cladribine {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Valrubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Cladribine may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Cladribine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Doxorubicin (Compound)
Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Doxorubicin (Compound)
Cladribine (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Doxorubicin (Compound)
Cladribine (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is downregulated by Doxorubicin (Compound)
Cladribine (Compound) upregulates FOSL1 (Gene) and FOSL1 (Gene) is downregulated by Doxorubicin (Compound)
Cladribine (Compound) binds DCK (Gene) and DCK (Gene) is downregulated by Doxorubicin (Compound)
Cladribine (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Doxorubicin (Compound)
Cladribine (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Doxorubicin (Compound) and TOP2A (Gene) is downregulated by Doxorubicin (Compound)
Cladribine may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin (Compound) resembles Valrubicin (Compound) and Valrubicin (Compound) resembles Doxorubicin (Compound)